The MD&A dated March 26, 2018 is posted to SEDAR. A few things caught my eye:

"We are currently conducting two clinical trials with ZEN-3694, a single agent trial, which has been completed (enrollment closed, database locked, study report pending), and a Phase 1b/2a combination trial in mCRPC with enzalutamide, both described below."

The "study report pending" caught my eye. I wonder if a news release will follow the release of the study report.

"The trial has now been completed and met its primary safety endpoints and identified a maximum tolerated daily dose of 60mg for the single agent (ZEN-3694) and provided valuable pharmacokinetic data."

MTD of 60 mg for single agent ZEN-3694. I recall Zenith stating that they could use a lower ZEN-3694 dose in combo with enzalutamide, relative to single agent, to achieve cancer response.

"We also look to expand the development of ZEN-3694 into other solid tumor cancers (for example, ER+ breast cancer), as well as expanding our platform with other novel epigenetic targets."

Interesting that they used "novel epigenetic targets" and not just other BET inhibitors.